Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note published on Wednesday morning,Benzinga reports. Chardan Capital currently has a $14.00 price target on the stock.

COYA has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Roth Capital began coverage on shares of Coya Therapeutics in a research report on Friday, June 5th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.33.

Coya Therapeutics Trading Up 2.6%

NASDAQ:COYA opened at $4.79 on Wednesday. Coya Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.75. The stock has a market capitalization of $112.37 million, a price-to-earnings ratio of -4.48 and a beta of 0.60. The firm has a fifty day simple moving average of $4.87 and a two-hundred day simple moving average of $4.67.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Equities analysts predict that Coya Therapeutics will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics during the 3rd quarter valued at about $28,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth $47,000. Occudo Quantitative Strategies LP bought a new position in shares of Coya Therapeutics during the fourth quarter valued at $66,000. Oppenheimer & Co. Inc. bought a new position in shares of Coya Therapeutics during the fourth quarter valued at $81,000. Finally, Cetera Investment Advisers grew its position in Coya Therapeutics by 36.4% during the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after purchasing an additional 8,000 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.